Kura Oncology

KURANasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$1.044 B

$11.73 +1.12%

Close of 22 Sept 2026

Revenue

$67.5M

#2635 by revenue

Earnings

-$278.7M

Loss-making

Shares outstanding

88,960,619

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#155Obsidian TherapeuticsOBX$1.05B
#156AlumisALMS$1.05B
#157Kura OncologyKURA$1.04B
#158Amphastar PharmaceuticalsAMPH$1.03B
#159Arbutus BiopharmaABUS$991.2M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Kura Oncology, worth $1.11M. Grants and option exercises are excluded.

Troy Edward WilsonPresident and CEO$1.11M
100,000 shares at $11.12 on 17 Aug 2026 · filed 17 Aug 2026

What if Kura Oncology were worth as much as…

Open the what-if tool →

Gold $30.2T

$339,857.91

Per share 28,973× higher

Bitcoin $1.74T

$19,577.82

Per share 1,669× higher

Nvidia $5.52T

$62,002.35

Per share 5,286× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Kura Oncology are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.